Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSUPP.L Regulatory News (SUPP)

  • There is currently no data for SUPP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Portfolio Manager Appointment and Change of Name

13 Dec 2019 13:35

RNS Number : 8683W
Woodford Patient Capital Trust PLC
13 December 2019
 

13 December 2019

 

Schroder UK Public Private Trust plc

 

Portfolio Manager Appointment

and Change of Name

 

The Board of Schroder UK Public Private Trust plc (previously Woodford Patient Capital Trust plc) (the "Company") is pleased to announce that Schroder Investment Management Limited ("Schroders") has been appointed as the Company's portfolio manager, effective immediately.

 

The Company has today been renamed Schroder UK Public Private Trust plc and the ordinary shares will trade under the TIDM "SUPP" with effect from 8:00am on Monday 16 December 2019.

 

Further details on Schroder UK Public Private Trust plc can be found here:

http://www.schroders.com/publicprivatetrust 

 

Schroders employs a collaborative team-based approach, combining its skill, experience and significant research resources across both public listed equity, and private equity.

 

Schroders' Private Equity investment team, Schroder Adveq, has over 20 years' experience and a track record of successfully investing in early stage companies both direct via co-investment and through funds. Schroder Adveq has over £10 billion of assets under management across several specialist strategies. This includes investments in funds and companies and over 100 direct co-investments across Europe, US and Asia.

 

Schroders will leverage its stock selection expertise from across its public equities teams, as well as its wider investment capabilities in Data Insights and Sustainability. The aim will be to exploit the very best of Schroders' long-term fundamental equity analysis in pursuit of identifying leading businesses of the decades ahead.

 

Susan Searle, Chair, commented:

 

"I am extremely pleased to announce the appointment of Schroders as the Company's portfolio manager. Following a smooth handover, the Board is confident that the portfolio manager's expertise in both public and private assets, alongside its deep sector experience, will enable the portfolio to deliver sustainable value and positive long-term shareholder returns.

 

I have been highly impressed with the Schroders team and their approach, having worked closely with them during the transition. The Board and I look forward to keeping shareholders updated as Schroders gets started as our new portfolio manager."

 

Schroders commented:

 

"Schroders is delighted to have been given the opportunity to manage this portfolio. The investment strategy we will utilise for the mandate, with its focus on investment in both public markets and private assets, reflects one of our key strategic growth areas across our business. We are also pleased that the borrowing facility has been extended for a 12-month period, allowing time for a considered approach to de-gearing the portfolio and providing the portfolio managers more flexibility in managing the Company's assets for the benefit of the shareholders."

 

As detailed in the Portfolio Manager Appointment announcement on 24 October 2019, Schroders will not take a management fee for three months; thereafter Schroders will be paid a management fee at the rate of 1.0% per annum on market capitalisation up to £600 million and 0.8% per annum thereafter.

 

There is no performance fee payable until 31 December 2022, at which point Schroders will be eligible to a fee of 15% of any excess returns above a NAV per share of 77p. Thereafter a performance fee of 15% of any performance above a Target NAV will be payable where the Target NAV is equal to: (i) 110% of the NAV at the time the performance fee was last paid; or (ii) 77p if no performance fee has been paid.

 

This announcement contains Inside Information as defined under the Market Abuse Regulation (EU) No. 596/2014.

 

 

LEI: 2138008X94M7OVE73I77

 

-Ends-

 

 

Enquiries:

 

FTI Consulting

 

Ed Berry / Tom Blackwell 0203 727 1046 / 1051

 

 

Schroders

 

Estelle Bibby 0207 658 3431

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCZMMMZFFRGLZM
Date   Source Headline
10th Dec 202110:25 amRNSNet Asset Value(s)
9th Dec 202110:53 amRNSNet Asset Value(s)
8th Dec 20215:34 pmRNSHolding(s) in Company
8th Dec 202111:17 amRNSNet Asset Value(s)
7th Dec 202111:35 amRNSNet Asset Value(s)
6th Dec 202110:31 amRNSNet Asset Value(s)
6th Dec 20217:00 amRNSBenevolentAI Transaction
3rd Dec 20214:34 pmRNSInvestment in Ada Health
3rd Dec 202110:40 amRNSNet Asset Value(s)
2nd Dec 20214:40 pmRNSSecond Price Monitoring Extn
2nd Dec 20214:35 pmRNSPrice Monitoring Extension
2nd Dec 202111:10 amRNSNet Asset Value(s)
1st Dec 20211:00 pmRNSAsset Sale
1st Dec 202110:58 amRNSNet Asset Value(s)
30th Nov 20214:12 pmRNSNet Asset Value(s)
29th Nov 20211:35 pmRNSNet Asset Value(s)
29th Nov 20217:00 amRNSNet Asset Value(s) Q3
26th Nov 20212:38 pmRNSNet Asset Value(s)
25th Nov 202111:15 amRNSNet Asset Value(s)
24th Nov 20211:08 pmRNSNet Asset Value(s)
23rd Nov 202111:26 amRNSNet Asset Value(s)
22nd Nov 202111:08 amRNSNet Asset Value(s)
19th Nov 202111:50 amRNSNet Asset Value(s)
18th Nov 202111:03 amRNSNet Asset Value(s)
18th Nov 20217:00 amRNSInvestment in Attest
17th Nov 202111:39 amRNSNet Asset Value(s)
16th Nov 202111:06 amRNSNet Asset Value(s)
15th Nov 202112:05 pmRNSNet Asset Value(s)
12th Nov 202111:05 amRNSNet Asset Value(s)
11th Nov 202112:00 pmRNSNet Asset Value(s)
10th Nov 20211:49 pmRNSHolding(s) in Company
10th Nov 202111:31 amRNSNet Asset Value(s)
9th Nov 202112:30 pmRNSNet Asset Value(s)
8th Nov 20211:01 pmRNSNet Asset Value(s)
5th Nov 202111:33 amRNSNet Asset Value(s)
4th Nov 202112:39 pmRNSNet Asset Value(s)
3rd Nov 202111:48 amRNSNet Asset Value(s)
2nd Nov 202112:59 pmRNSNet Asset Value(s)
1st Nov 20213:38 pmRNSMove to Daily Pricing
15th Oct 202111:54 amRNSHolding(s) in Company
8th Oct 20214:40 pmRNSSecond Price Monitoring Extn
8th Oct 20214:36 pmRNSPrice Monitoring Extension
30th Sep 202110:09 amRNSOxford Nanopore Completes IPO
21st Sep 20217:00 amRNSHalf-year Report
16th Sep 20219:14 amRNSOxford Nanopore Files Notice of Intention to Float
10th Sep 20212:22 pmRNSOxford Nanopore expected intention to float
25th Aug 20217:00 amRNSBlock listing Interim Review
9th Aug 20217:00 amRNSInvestment in Revolut
21st Jun 20217:00 amRNSNeoGenomics completes Inivata acquisition
4th Jun 20215:25 pmRNSAGM Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.